ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
27 févr. 2019 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
BioSig Announces Expansion of Engineering Team
26 févr. 2019 07h52 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Feb. 26, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
BioSig Announces Successful First-In-Human Use of PURE EP System
20 févr. 2019 07h52 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Feb. 20, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
20 févr. 2019 07h30 HE
|
ARCA biopharma, Inc.
FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
BioSig Technologies Inc. Issues 2019 Shareholder Letter
12 févr. 2019 07h52 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
BioSig Appoints John Kowalski to Lead Commercialization of PURE EP
05 févr. 2019 07h52 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Feb. 05, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
20 déc. 2018 16h01 HE
|
ARCA biopharma, Inc.
Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...
Johnson & Johnson's Biosense Webster’s MaryAnn Edzards Joins BioSig
19 déc. 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Dec. 19, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
BioSig Technologies To Commence First–in-Human Studies at Mayo Clinic
06 déc. 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Dec. 06, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...
Medical Leaders Join BioSig Clinical Advisory Board
28 nov. 2018 08h00 HE
|
BioSig Technologies, Inc.
Santa Monica, CA, Nov. 28, 2018 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to...